Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	2.765 $	+2.41%	141,260
26-06-11	2.700 $	+6.30%	1,156,442
26-06-10	2.540 $	-1.17%	762,512
26-06-09	2.570 $	-6.20%	1,129,218
26-06-08	2.740 $	-2.84%	649,253

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.700USD

Average target price

4.000USD

Spread / Average Target

+48.15%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:37:37 2026-06-12 EDT			5-day change	1st Jan Change
2.785 ^USD	+3.15%		-1.95%	+18.67%

05-13	Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	Spero Therapeutics Q4 Swings to Profit, Revenue Rises	MT

Market Cap	156M 136M 125M 117M 219M 14.97B 223M 1.49B 578M 7.22B 587M 574M 25.09B	P/E Ratio 2024	-0.81x	P/E Ratio 2025	15.5x
Enterprise Value	156M 136M 125M 117M 219M 14.97B 223M 1.49B 578M 7.22B 587M 574M 25.09B	EV / Sales 2024	1,170,430x	EV / Sales 2025	-
Free-Float	77.48%	Yield 2024 *	-	Yield 2025	-

05-13	Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	Spero Therapeutics Q4 Swings to Profit, Revenue Rises	MT
03-26	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-30	Spero Therapeutics, Inc. Announces Resignation of Ankit Mahadevia, Md from Board of Directors and from His Service on the Development Committee and from All Officer and Director Positions He Holds with Any and All Subsidiaries, Effective January 30, 2026	CI
12-19	Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis	CI
12-19	Spero announces NDA resubmission of tebipenem HBr by GSK to the FDA	RE
12-19	Spero Therapeutics Says GSK Resubmits NDA; Triggers $25 Million Milestone	MT
11-13	Spero Therapeutics Q3 net loss narrows	RE
11-13	Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-21	Spero Therapeutics Reports Primary Endpoint Success in Urinary Tract Infections Phase 3 Study; Shares Jump Premarket	MT
25-10-21	GSK and Spero publish positive results for experimental antibiotic
25-10-21	GSK reports positive updates on Shingrix and tebipenem HBr	AN
25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI

25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
24-12-20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
24-11-18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
24-08-06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
23-08-14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

Spero Therapeutics, Inc. Stock

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Valuation: Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript: Spero Therapeutics, Inc.

Analysts' recommendations: Spero Therapeutics, Inc.

Press Releases: Spero Therapeutics, Inc.

News in other languages: Spero Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Spero Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

05-13	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update	AQ
05-05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
03-26	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update	AQ
03-18	Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026	AQ
01-30	SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures	AQ

25-10-21	GSK et Spero publient des résultats positifs sur un antibiotique expérimental
25-05-28	GSK : arrêt anticipé d'un essai de phase III réussi
25-05-28	USA-Les valeurs à suivre à Wall Street (actualisé)
22-09-23	USA-Les valeurs à suivre à Wall Street (actualisé)
22-09-22	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	+3.15%
1 week	-1.95%
Current month	-2.30%
1 month	+8.86%
3 months	+6.76%
6 months	+19.18%
Current year	+18.67%

1 week	2.48	2.87
1 month	2.37	3.08
Current year	2.1	3.08
1 year	1.8	3.22
3 years	0.51	3.22
5 years	0.51	19.87
10 years	0.51	23.64

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	2025-01-09
Timothy Keutzer COO	Chief Operating Officer	58	2023-01-31
Shai Biran IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	2013-12-31
Patrick Volkert Vink BRD	Director/Board Member	62	2015-08-31
Frank Thomas CHM	Chairman	56	2025-01-09

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-03	Esther Rajavelu	Sell	Chief Executive Officer	-25,240	0.0436%
02-05	Esther Rajavelu	Sell	Chief Executive Officer	87,917	0.1560%
02-05	Timothy Keutzer	Sell	Chief Operating Officer	18,652	0.0331%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	+3.15%	-1.95%	-4.33%	+58.00%	156M
ARGENX SE	+0.77%	+2.04%	+54.53%	+111.24%	55.58B
WUXI APPTEC CO., LTD.	+0.03%	+0.33%	+49.22%	+43.94%	43.47B
BIONTECH SE	+0.61%	+1.80%	-14.54%	-18.33%	22.64B
INSMED INCORPORATED	+0.53%	+3.65%	+0.81%	+400.82%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+12.00%	-29.52%	15.79B
GENMAB A/S	+0.45%	+0.53%	+9.13%	-40.02%	15.3B
EXELIXIS, INC.	+0.27%	+1.95%	+28.60%	+181.46%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+14.25%	-	11.74B
PHARMAESSENTIA CORPORATION	-5.27%	-0.43%	+87.77%	+208.02%	10.96B
Average	+0.94%	-1.32%	+23.74%	+101.73%	21.01B
Weighted average by Cap.	+0.67%	+0.76%	+31.90%	+99.50%

	2024	2025
Net sales	47.98M 41.63M 38.38M 35.96M 67.19M 4.59B 68.59M 458M 177M 2.21B 180M 176M 7.7B	66.8M 57.97M 53.44M 50.07M 93.55M 6.4B 95.5M 637M 247M 3.08B 251M 245M 10.72B
Net income	-68.57M -59.5M -54.85M -51.39M -96.02M -6.57B -98.02M -654M -253M -3.16B -257M -252M -11B	8.57M 7.44M 6.86M 6.42M 12M 821M 12.25M 81.8M 31.67M 396M 32.18M 31.49M 1.38B
Net Debt	-	-